AbbVie Inc (ABBV)

72.41
0.33 0.45
NYSE : Health Care
Prev Close 72.74
Open 72.67
Day Low/High 72.25 / 73.06
52 Wk Low/High 55.06 / 73.67
Volume 4.48M
Avg Volume 5.70M
Exchange NYSE
Shares Outstanding 1.59B
Market Cap 115.61B
EPS 3.60
P/E Ratio 14.38
Div & Yield 2.56 (3.50%)

Latest News

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.

AbbVie Receives CHMP Positive Opinion For MAVIRET™ (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

- If approved, MAVIRET™ will provide a shorter, 8-week, pan-genotypic (GT1-6), once-daily option for the majority of people living with the hepatitis C virus (HCV)(1)*

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.

AbbVie Declares Quarterly Dividend

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat

AbbVie Has Just Broken Out to the Upside and It Could Probably Keep Climbing Much Higher

AbbVie Has Just Broken Out to the Upside and It Could Probably Keep Climbing Much Higher

AbbVie's June rally has now driven shares past the 2016 high.

New Data Presented At ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer A More Targeted Approach To Chronic Lymphocytic Leukemia (CLL) Treatment Than Chemotherapy Agent Chlorambucil In Treatment-Naive Patients

- IMBRUVICA effectively impacted cancerous cells while sparing non-cancerous white blood cells through one year of treatment

Long-Term IMBRUVICA® (ibrutinib) Efficacy And Safety Data At ASCO 2017 Show Sustained Survival Rates In Up To Four Years In Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those With High-Risk Disease

- Data show 59 percent progression free survival and 74 percent overall survival in CLL/SLL patients treated with IMBRUVICA, with high-risk patients trending to have the most favorable outcome[1]

S&P 500, Nasdaq Edge Higher as Crude Rebounds From Thursday Slump

S&P 500, Nasdaq Edge Higher as Crude Rebounds From Thursday Slump

Stocks are narrowly mixed on Friday, putting the S&P 500 and Nasdaq at risk of snapping a six-day winning streak.

Wall Street Weighs In on Athenahealth's Strategic Options

Wall Street Weighs In on Athenahealth's Strategic Options

Elliott's previous successes in the healthcare space bode well for its chances at athena.

AbbVie Presents Pivotal Phase 3 Data On Investigational Treatment Elagolix At The World Congress On Endometriosis

- Primary and secondary efficacy and safety data to be presented from two pivotal Phase 3 studies evaluating the use of elagolix in endometriosis-associated pain

AbbVie Stock Lower on Humira Patent Ruling

AbbVie Stock Lower on Humira Patent Ruling

The drug is responsible for more than 60% of AbbVie's top line.

AbbVie, Broadcom, Enbridge Energy Partners, Commercial Vehicle Group: 'Mad Money' Lightning Round

AbbVie, Broadcom, Enbridge Energy Partners, Commercial Vehicle Group: 'Mad Money' Lightning Round

Jim Cramer is bullish on AbbVie, Broadcom, Enbridge Energy Partners, and Commercial Vehicle Group.

Industrials Are Stalling, Techs Are Roaring: Cramer's 'Mad Money' Recap (Monday 5/15/17)

Industrials Are Stalling, Techs Are Roaring: Cramer's 'Mad Money' Recap (Monday 5/15/17)

Jim Cramer says investors are migrating toward sectors likely to have the biggest upside in the second half.

AbbVie Announces Positive Phase 2 Study Results For Upadacitinib (ABT-494), An Investigational JAK1-Selective Inhibitor, In Crohn's Disease

- Phase 2 study showed positive results in a moderately to severely active Crohn's disease patient population, the majority of whom had previously failed two or more biologics

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.

AbbVie Demonstrates Leadership In Gastroenterology And Hepatology With New Data And Late-Breaking Studies To Be Presented At Digestive Disease Week®

- Phase 2 late-breaking study evaluates upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderately to severely active Crohn's disease, the majority of whom had failed two or more biologics

Earnings: Assessing 3 Biotech Bellwethers

Earnings: Assessing 3 Biotech Bellwethers

How did Celgene, AbbVie and Gilead fare last quarter?

Between Amazon and Alphabet; Oil Dominoes: Jim Cramer's View

Between Amazon and Alphabet; Oil Dominoes: Jim Cramer's View

Cramer shares his views on which is better: Amazon or Alphabet, and discusses the domino effect when oil falls.

Domino Effect of Falling Oil Prices: Cramer's 'Mad Money' Recap (Thursday 4/27/17)

Domino Effect of Falling Oil Prices: Cramer's 'Mad Money' Recap (Thursday 4/27/17)

Jim Cramer says this market is strong enough to withstand falling oil prices and a tax plan that will face a lot of obstacles.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Cramer: When Oil Falls, These Dominoes Get Hit

Cramer: When Oil Falls, These Dominoes Get Hit

It doesn't look like Washington will be much help.

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

Stocks hold onto slight to modest gains Thursday afternoon after positive earnings help to offset a slump in crude oil prices and a decline in energy names.